RYBREVANT® (AMIVANTAMAB-VMJW) PLUS LAZCLUZE™ (LAZERTINIB) SHOW STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL VERSUS OSIMERTINIB

Reuters · 01/07 13:00

Please log in to view news